advanced lung cancer
Conditions
Interventions
Immunonutrition support:In this study, the experimental group will receive 2-3 bottles of oral immunonutrient supplements per day for a total of 10 days, starting after chemotherapy in each treatment
Control group:standard nutritional education and intervention
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Before any study-specific procedures, sampling, or analysis, the subject must sign a written informed consent form in accordance with current guidelines and indicate the date. 2. At the time of signing the informed consent form (ICF), the subject must be =18 years old. 3. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. 4. Histologically or cytologically confirmed malignancy of pulmonary origin. 5. Histologically or cytologically confirmed metastatic or locally advanced NSCLC, not suitable for curative treatment, and planned to receive chemotherapy-based treatment. 6. Expected survival of more than 6 months.
Exclusion criteria
Exclusion criteria: Subjects meeting any of the following criteria will be excluded: 1. Currently suffering from a hematologic malignancy. 2. Tumors of other pathological types that are histologically different from the tumor type in this study, except for carcinoma in situ of the cervix, ductal carcinoma in situ, prostate intraepithelial neoplasia, superficial non-invasive bladder cancer, and cured stage I skin cancer (excluding melanoma). 3. Known allergy to oral immunonutrients, oral nutrients, and their components. 4. Difficulty in oral feeding. 5. Coexisting autoimmune diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life (QLQ-C30) assessed by researchers after 2 cycles of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (TRAEs) as assessed by researchers; | — |
Countries
China
Contacts
Public ContactJiuwei Cui
The First Hospital of Jilin University
Outcome results
None listed